-- 独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下：我们12个月的目标价为153美元，上调16美元，该目标价综合考虑了相对估值和现金流折现模型。相对估值方面，我们对2027年预计EBITDA采用5.2倍的企业价值倍数，与EOG的历史预期平均水平基本一致，得出每股价值125美元。同时，我们的现金流折现模型假设中期自由现金流增长率为5.0%，终端增长率为2.5%，并以7.1%的加权平均资本成本（WACC）进行折现，得出每股内在价值181美元。我们将2026年每股收益（EPS）预期上调6.25美元至15.75美元，并将2027年每股收益预期上调1.54美元至13.17美元。 EOG的生产结构仍然以液体产品为主（占2026年预期产量的63%），但在完成对Encino的收购后，这一比例已显著下降。EOG在第一季度确实面临一些成本压力，我们认为这与消化Encino的收购有关（该收购将于2025年第三季度完成），但我们注意到该公司在提高成本效益方面有着长期良好的记录，并预计其将在不久的将来重回正轨。
Related Articles
Mining & Metals
5N Plus Q1 Revenue of US$117.9 million, up 33% YoY
$VNP.TO
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Davita Inc.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Our 12-month target price is $220 (raised from $175), based on a P/E multiple of 15x our 2026 EPS projection, above DVA's five-year historical average of 13.1x and above our target multiple for DVA's primary competitor Fresenius Medical Care. We think our target multiple balances strong earnings growth expectations against elevated debt levels and recent challenges with consistent treatment volume growth. Our 2026 EPS estimate is $14.65 (up from $14.08, implying 36% annual growth), while our 2027 estimate is $16.67 (up from $16.33, +13.8% Y/Y). We anticipate revenue will rise near 4% in 2026 and 3% in 2027, after increasing 6.5% in 2025, supported by market share gains following center closures by competitor Fresenius. Q1 treatment volume growth remained challenging with normalized non-acquired growth of just 0.1% Y/Y. However, DVA raised guidance for treatment volumes from flat to a 0.25%-0.50% growth rate in 2026, providing expectations for improving growth in upcoming quarters.
$DVA
Equities
Earnings Flash (PR) Permian Resources Posts Q1 Adjusted EPS $0.39, vs. FactSet Est of $0.38
$PR